Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Article Details

Citation

Copy to clipboard

Lenert P

Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Clin Exp Immunol. 2005 Apr;140(1):1-10.

PubMed ID

15762869 [ View in PubMed

]

Abstract

Recent studies have shed new light on a possible link between the innate activation of plasmocytoid dendritic cells and marginal zone B cells and the pathogenesis of systemic lupus erythematosus. Animal studies have identified that this response requires the Toll-like receptor 9 (TLR9). Engagement of the TLR9 by various ligands, including non-canonical CpG-motifs, can cause or aggravate pathogenic autoantibody production and cytokine secretion in lupus. Attempts to neutralize this activity either by blocking the acidification of the endosomal compartment with chloroquine and related compounds, or by preventing the interaction between the CpG-DNA sequences and TLR9 using inhibitory oligonucleotides could be a promising therapeutic option for lupus.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Chloroquine	Toll-like receptor 9	Protein	Humans	Unknown	Inhibitor	Details